Gobia Enterprises invests in Dx4Life

Gobia Enterprises has joined forces with Dx4Life, a pioneering company aiming to revolutionize fertility treatments through personalized medicine. By participating in the company's first funding round, Gobia supports Dx4Life’s mission to improve the chances of pregnancy for couples struggling with infertility.

Dx4Life, founded in collaboration with Lund University and LU Holding, has developed a groundbreaking genetic test that optimizes hormone treatments for IVF patients. The test ensures that each patient receives a personalized hormone protocol, increasing the likelihood of pregnancy while reducing potential side effects.

“The research behind this test is the result of eight years of dedicated work at Lund University, studying hormonal impact on fertility. We are confident that this innovation will transform IVF treatments and bring hope to thousands of couples facing infertility,” says Professor Yvonne Lundberg Giwercman, one of the key researchers behind Dx4Life.

The investment will be used for CE certification and product launch, with CE marking targeted for late 2025 and market entry in Q1 2026. As part of the funding round, Gobia Enterprises has joined Dx4Life’s ownership structure, and Erik Brobjer has taken a seat on the board.

“Dx4Life is an incredibly exciting company with great potential to become a leader in its niche within IVF. Furthermore, we see strong growth opportunities in the company’s technological platform,” says Erik Brobjer, Gobia Enterprises representative.

Read the full article from Lund University here.